[Experimental and clinical studies on intravesical instillation therapy for bladder cancer].
Intravesical instillation therapy was performed in 155 cases of urinary bladder cancer. In 60% of the patients treated by therapeutic intravesical instillation, antitumor effects were observed. The patients who were given only the instillation therapy frequently had recurrence of the tumor in the same site within one year. Therefore, in such cases prophylactic instillation seems to be necessary. The preventive effect of intermittent instillation therapy given over a long period was superior to that of concentrated instillation therapy given during a short period. The rate of recurring bladder tumors decreased after instillation therapy. Eight cases that were cystoscopically nonvisual tumors but indicated positive cytology were treated by intravesical instillation therapy. In 5 of these cases cytology was negative after treatment.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002225:Carbazilquinone / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000188:drug therapy*; D003581:Cytodiagnosis; D004317:Doxorubicin / Q000008:administration & dosage; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007267:Injections / Q000379:methods; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
D008937:Mitomycins; D002225:Carbazilquinone; D016685:Mitomycin; D004317:Doxorubicin